DENTSPLY SIRONA INC (XRAY) Fundamental Analysis & Valuation

NASDAQ:XRAY • US24906P1093

Current stock price

12.51 USD
+0.42 (+3.47%)
At close:
12.76 USD
+0.25 (+2%)
After Hours:

This XRAY fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

4

1. XRAY Profitability Analysis

1.1 Basic Checks

  • XRAY had positive earnings in the past year.
  • In the past year XRAY had a positive cash flow from operations.
  • XRAY had negative earnings in 4 of the past 5 years.
  • XRAY had a positive operating cash flow in each of the past 5 years.
XRAY Yearly Net Income VS EBIT VS OCF VS FCFXRAY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M -500M -1B -1.5B

1.2 Ratios

  • With a Return On Assets value of -11.01%, XRAY perfoms like the industry average, outperforming 58.51% of the companies in the same industry.
  • XRAY's Return On Equity of -44.66% is in line compared to the rest of the industry. XRAY outperforms 50.53% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 4.89%, XRAY is in the better half of the industry, outperforming 75.00% of the companies in the same industry.
  • The Average Return On Invested Capital over the past 3 years for XRAY is below the industry average of 9.15%.
  • The 3 year average ROIC (4.23%) for XRAY is below the current ROIC(4.89%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA -11.01%
ROE -44.66%
ROIC 4.89%
ROA(3y)-9.54%
ROA(5y)-7.32%
ROE(3y)-31.84%
ROE(5y)-22.45%
ROIC(3y)4.23%
ROIC(5y)4.67%
XRAY Yearly ROA, ROE, ROICXRAY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -10 -20 -30 -40

1.3 Margins

  • The Operating Margin of XRAY (6.88%) is better than 72.87% of its industry peers.
  • XRAY's Operating Margin has declined in the last couple of years.
  • XRAY has a Gross Margin of 50.00%. This is comparable to the rest of the industry: XRAY outperforms 46.28% of its industry peers.
  • XRAY's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 6.88%
PM (TTM) N/A
GM 50%
OM growth 3Y-9.52%
OM growth 5Y-3.69%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.67%
GM growth 5Y-0.36%
XRAY Yearly Profit, Operating, Gross MarginsXRAY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. XRAY Health Analysis

2.1 Basic Checks

  • XRAY has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • Compared to 1 year ago, XRAY has more shares outstanding
  • Compared to 5 years ago, XRAY has less shares outstanding
  • The debt/assets ratio for XRAY is higher compared to a year ago.
XRAY Yearly Shares OutstandingXRAY Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M
XRAY Yearly Total Debt VS Total AssetsXRAY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B 10B

2.2 Solvency

  • Based on the Altman-Z score of 0.93, we must say that XRAY is in the distress zone and has some risk of bankruptcy.
  • XRAY has a Altman-Z score of 0.93. This is comparable to the rest of the industry: XRAY outperforms 48.94% of its industry peers.
  • XRAY has a debt to FCF ratio of 22.38. This is a negative value and a sign of low solvency as XRAY would need 22.38 years to pay back of all of its debts.
  • XRAY has a Debt to FCF ratio of 22.38. This is in the better half of the industry: XRAY outperforms 67.02% of its industry peers.
  • A Debt/Equity ratio of 1.50 is on the high side and indicates that XRAY has dependencies on debt financing.
  • XRAY has a Debt to Equity ratio of 1.50. This is amonst the worse of the industry: XRAY underperforms 80.32% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.5
Debt/FCF 22.38
Altman-Z 0.93
ROIC/WACC0.83
WACC5.87%
XRAY Yearly LT Debt VS Equity VS FCFXRAY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B

2.3 Liquidity

  • XRAY has a Current Ratio of 1.51. This is a normal value and indicates that XRAY is financially healthy and should not expect problems in meeting its short term obligations.
  • XRAY has a worse Current ratio (1.51) than 77.13% of its industry peers.
  • A Quick Ratio of 1.03 indicates that XRAY should not have too much problems paying its short term obligations.
  • XRAY's Quick ratio of 1.03 is on the low side compared to the rest of the industry. XRAY is outperformed by 81.91% of its industry peers.
Industry RankSector Rank
Current Ratio 1.51
Quick Ratio 1.03
XRAY Yearly Current Assets VS Current LiabilitesXRAY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. XRAY Growth Analysis

3.1 Past

  • XRAY shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -4.79%.
  • The Earnings Per Share has been decreasing by -2.34% on average over the past years.
  • The Revenue has decreased by -2.98% in the past year.
  • XRAY shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 1.96% yearly.
EPS 1Y (TTM)-4.79%
EPS 3Y-8.57%
EPS 5Y-2.34%
EPS Q2Q%3.85%
Revenue 1Y (TTM)-2.98%
Revenue growth 3Y-2.1%
Revenue growth 5Y1.96%
Sales Q2Q%6.19%

3.2 Future

  • XRAY is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 4.14% yearly.
  • Based on estimates for the next years, XRAY will show a small growth in Revenue. The Revenue will grow by 1.31% on average per year.
EPS Next Y-8.16%
EPS Next 2Y-0.15%
EPS Next 3Y3.75%
EPS Next 5Y4.14%
Revenue Next Year-1.83%
Revenue Next 2Y0.09%
Revenue Next 3Y1.06%
Revenue Next 5Y1.31%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
XRAY Yearly Revenue VS EstimatesXRAY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 1B 2B 3B 4B
XRAY Yearly EPS VS EstimatesXRAY Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0.5 1 1.5 2 2.5

More info and screens

Find the best growth stocksShow best growing peers

7

4. XRAY Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 7.87, the valuation of XRAY can be described as very cheap.
  • XRAY's Price/Earnings ratio is rather cheap when compared to the industry. XRAY is cheaper than 96.28% of the companies in the same industry.
  • XRAY's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.87.
  • The Price/Forward Earnings ratio is 8.57, which indicates a very decent valuation of XRAY.
  • 96.81% of the companies in the same industry are more expensive than XRAY, based on the Price/Forward Earnings ratio.
  • XRAY's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 38.51.
Industry RankSector Rank
PE 7.87
Fwd PE 8.57
XRAY Price Earnings VS Forward Price EarningsXRAY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of XRAY indicates a rather cheap valuation: XRAY is cheaper than 95.74% of the companies listed in the same industry.
  • 85.11% of the companies in the same industry are more expensive than XRAY, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 24.03
EV/EBITDA 7.3
XRAY Per share dataXRAY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-0.15%
EPS Next 3Y3.75%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

7

5. XRAY Dividend Analysis

5.1 Amount

  • With a Yearly Dividend Yield of 5.50%, XRAY is a good candidate for dividend investing.
  • XRAY's Dividend Yield is rather good when compared to the industry average which is at 0.25. XRAY pays more dividend than 99.47% of the companies in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.82, XRAY pays a better dividend.
Industry RankSector Rank
Dividend Yield 5.5%

5.2 History

  • On average, the dividend of XRAY grows each year by 9.95%, which is quite nice.
  • XRAY has been paying a dividend for at least 10 years, so it has a reliable track record.
  • XRAY has not decreased its dividend for at least 10 years, so it has a reliable track record of non decreasing dividend.
Dividend Growth(5Y)9.95%
Div Incr Years0
Div Non Decr Years31
XRAY Yearly Dividends per shareXRAY Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0.2 0.4 0.6

5.3 Sustainability

  • XRAY has negative earnings and hence a negative payout ratio. The dividend may be in danger.
  • The dividend of XRAY is growing, but the earnings are growing slower. This means the dividend growth is not sustainable.
DP-21.4%
EPS Next 2Y-0.15%
EPS Next 3Y3.75%
XRAY Yearly Income VS Free CF VS DividendXRAY Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M -500M -1B -1.5B

More info and screens

Find the best dividend stocksShow peers with best dividend

XRAY Fundamentals: All Metrics, Ratios and Statistics

DENTSPLY SIRONA INC

NASDAQ:XRAY (4/17/2026, 8:00:02 PM)

After market: 12.76 +0.25 (+2%)

12.51

+0.42 (+3.47%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-26
Earnings (Next)05-06
Inst Owners109.59%
Inst Owner Change-0.01%
Ins Owners0.37%
Ins Owner Change5.31%
Market Cap2.50B
Revenue(TTM)3.68B
Net Income(TTM)-598.00M
Analysts70.48
Price Target14.71 (17.59%)
Short Float %10.32%
Short Ratio4.3
Dividend
Industry RankSector Rank
Dividend Yield 5.5%
Yearly Dividend0.64
Dividend Growth(5Y)9.95%
DP-21.4%
Div Incr Years0
Div Non Decr Years31
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-11.91%
Min EPS beat(2)-19.03%
Max EPS beat(2)-4.78%
EPS beat(4)2
Avg EPS beat(4)5.76%
Min EPS beat(4)-19.03%
Max EPS beat(4)45.37%
EPS beat(8)3
Avg EPS beat(8)-2.22%
EPS beat(12)5
Avg EPS beat(12)0.84%
EPS beat(16)7
Avg EPS beat(16)2.02%
Revenue beat(2)1
Avg Revenue beat(2)0.23%
Min Revenue beat(2)-1.16%
Max Revenue beat(2)1.63%
Revenue beat(4)2
Avg Revenue beat(4)-0.11%
Min Revenue beat(4)-1.67%
Max Revenue beat(4)1.63%
Revenue beat(8)2
Avg Revenue beat(8)-1.43%
Revenue beat(12)5
Avg Revenue beat(12)-0.96%
Revenue beat(16)6
Avg Revenue beat(16)-1.46%
PT rev (1m)11.25%
PT rev (3m)15.06%
EPS NQ rev (1m)-4.57%
EPS NQ rev (3m)-25.24%
EPS NY rev (1m)-0.4%
EPS NY rev (3m)-8.65%
Revenue NQ rev (1m)0.29%
Revenue NQ rev (3m)-5.53%
Revenue NY rev (1m)-0.19%
Revenue NY rev (3m)-2.54%
Valuation
Industry RankSector Rank
PE 7.87
Fwd PE 8.57
P/S 0.68
P/FCF 24.03
P/OCF 10.63
P/B 1.87
P/tB N/A
EV/EBITDA 7.3
EPS(TTM)1.59
EY12.71%
EPS(NY)1.46
Fwd EY11.67%
FCF(TTM)0.52
FCFY4.16%
OCF(TTM)1.18
OCFY9.4%
SpS18.42
BVpS6.7
TBVpS-3.92
PEG (NY)N/A
PEG (5Y)N/A
Graham Number15.4859 (23.79%)
Profitability
Industry RankSector Rank
ROA -11.01%
ROE -44.66%
ROCE 6.19%
ROIC 4.89%
ROICexc 5.32%
ROICexgc 12.2%
OM 6.88%
PM (TTM) N/A
GM 50%
FCFM 2.83%
ROA(3y)-9.54%
ROA(5y)-7.32%
ROE(3y)-31.84%
ROE(5y)-22.45%
ROIC(3y)4.23%
ROIC(5y)4.67%
ROICexc(3y)4.53%
ROICexc(5y)4.96%
ROICexgc(3y)13.19%
ROICexgc(5y)19.09%
ROCE(3y)5.56%
ROCE(5y)6.04%
ROICexgc growth 3Y-15.1%
ROICexgc growth 5Y-11.06%
ROICexc growth 3Y3.36%
ROICexc growth 5Y12.36%
OM growth 3Y-9.52%
OM growth 5Y-3.69%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.67%
GM growth 5Y-0.36%
F-Score5
Asset Turnover0.68
Health
Industry RankSector Rank
Debt/Equity 1.5
Debt/FCF 22.38
Debt/EBITDA 3.33
Cap/Depr 37.22%
Cap/Sales 3.56%
Interest Coverage 3.83
Cash Conversion 38.84%
Profit Quality N/A
Current Ratio 1.51
Quick Ratio 1.03
Altman-Z 0.93
F-Score5
WACC5.87%
ROIC/WACC0.83
Cap/Depr(3y)44.08%
Cap/Depr(5y)43.74%
Cap/Sales(3y)4.02%
Cap/Sales(5y)3.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-4.79%
EPS 3Y-8.57%
EPS 5Y-2.34%
EPS Q2Q%3.85%
EPS Next Y-8.16%
EPS Next 2Y-0.15%
EPS Next 3Y3.75%
EPS Next 5Y4.14%
Revenue 1Y (TTM)-2.98%
Revenue growth 3Y-2.1%
Revenue growth 5Y1.96%
Sales Q2Q%6.19%
Revenue Next Year-1.83%
Revenue Next 2Y0.09%
Revenue Next 3Y1.06%
Revenue Next 5Y1.31%
EBIT growth 1Y10%
EBIT growth 3Y-11.42%
EBIT growth 5Y-1.8%
EBIT Next Year16.8%
EBIT Next 3Y9.39%
EBIT Next 5Y10.04%
FCF growth 1Y-62.99%
FCF growth 3Y-34.38%
FCF growth 5Y-28.64%
OCF growth 1Y-49.02%
OCF growth 3Y-23.11%
OCF growth 5Y-18.39%

DENTSPLY SIRONA INC / XRAY Fundamental Analysis FAQ

What is the ChartMill fundamental rating of DENTSPLY SIRONA INC (XRAY) stock?

ChartMill assigns a fundamental rating of 4 / 10 to XRAY.


What is the valuation status for XRAY stock?

ChartMill assigns a valuation rating of 7 / 10 to DENTSPLY SIRONA INC (XRAY). This can be considered as Undervalued.


Can you provide the profitability details for DENTSPLY SIRONA INC?

DENTSPLY SIRONA INC (XRAY) has a profitability rating of 4 / 10.


How financially healthy is DENTSPLY SIRONA INC?

The financial health rating of DENTSPLY SIRONA INC (XRAY) is 3 / 10.


Can you provide the dividend sustainability for XRAY stock?

The dividend rating of DENTSPLY SIRONA INC (XRAY) is 7 / 10 and the dividend payout ratio is -21.4%.